Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine effects on neural circuitry in alcoholism vulnerability
NCT01585168Phase 2Completed
- Sponsor
- Yale University
- Start
- Dec 2011
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of memantine in alcohol use disorder (AUD) (4 arms), sponsored by Yale University. Primary endpoints: Change in Blood Oxygenation Level Dependent (BOLD) Activation in the Amygdala During 'Win' Monetary Incentive Delay (MID) Task and Change in Blood Oxygenation Level Dependent (BOLD) Activation in Anterior Cingulate Cortex During 'Loss' Condition of Monetary Incentive Delay (MID) Task. Started Dec 2011; status: completed.
02
Drugs
memantine
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT01585168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585168.